The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

Two new drugs will soon be available to target little-known forms of high cholesterol, which are driven by our genes and ...

High cholesterol often has no symptoms. Watch for shortness of breath, nausea, cold feet and legs, and slow-healing foot ...

Experts have started thinking more broadly about what puts a person at risk for heart disease, still the leading killer in the U.S.

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

There was a time when whisky was considered medicine. The spirit was used as an antiseptic on battlefields, and was sold in ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

New research describes how sphingolipids can also contribute to arterial plaques and atherosclerosis, revealing a new side to ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.